Core Insights - China's strategic layout is characterized by both "deep and broad" initiatives and "small and beautiful" approaches that focus on improving people's livelihoods in the Asia-Pacific region [2] - The opening of the Jakarta-Bandung High-Speed Railway in 2023 has facilitated over 12 million passenger trips [2] - A waste-to-energy plant in Hanoi, built with Chinese participation, processes 5,000 tons of waste daily, providing clean energy to approximately 180,000 households [2] - In Papua New Guinea, Chinese experts have trained around 3,000 individuals in low-cost agricultural technologies, benefiting thousands of locals [4] - Digital technologies from China are aiding hospitals in Bangkok, Thailand, in achieving smart transformation through 5G ambulances and AI-assisted diagnostics [6] - China is positioning itself as a leader in APEC cooperation, emphasizing trade facilitation, infrastructure projects, and shared experiences for mutual benefit [7] - The upcoming APEC summit in Shenzhen in 2026 is expected to focus on cooperation and innovation, showcasing the city's transformation from a fishing village to an innovation hub [8] - China's commitment to deepening reforms and expanding openness aims to foster a favorable external environment for high-quality development in the Asia-Pacific community [10] - The APEC "China Year" in 2026 will emphasize building a community for common prosperity and collaborative efforts among Asia-Pacific nations [12]

中国智慧和中国方案，不仅有"深而广"的战略布局，更有"小而美"的民生温度。从陆到海，从铁路到港口，中国以基建实力为亚太互联互通铺路搭桥，用务 实行动让亚太合作的红利惠及每一个普通民众。 中国承建的雅万高铁2023年开通，累计发送旅客超1200万人次。 在越南河内，一座由中国参与建造的垃圾发电站正高效运转。这里每天将5000吨生活垃圾，转化成清洁电能，点亮约18万户家庭的灯火，以绿色电力为当地 能源补给注入中国力量。 时任中治一治越南河内市垃圾焚烧项目经理 胡昌兵：以前这后面，黑色的下面全是垃圾。我当时就在想，无论在哪个国家，我们用绿色建造，让这个星球 生生不息。 从理念引领到贸易畅通，从基建工程到民生改善，从自身发展到经验共享，中国用实实在在的行动，成为APEC合作的引领者。这份贡献，彰显着中国与亚 太伙伴合作共赢的坚定初心。 2026年，世界的目光聚焦于中国深圳。这是一场探讨合作的盛会，更是一次面向未来的集结。深圳这座从渔村崛起的创新之城，将以广阔、开放的胸襟，迎 接这个盛会，让创新之光照亮亚太未来的发展之路。 外交部副部长 马朝旭：中国将进一步深化改革，扩大对外开放，推动建设亚太共同体，为构建新发展格局， ...

Group 1 - The core viewpoint is that AI in healthcare is integrated into national strategic planning, leading to an accelerated phase of industry development through a comprehensive policy framework [1][6] Group 2 - Infrastructure support focuses on standardization to enhance data interoperability and smart hospital construction, laying the groundwork for AI applications in healthcare [2] - Regulatory governance has established a tiered framework to balance innovation and safety, providing clear guidelines for AI medical software classification and lifecycle regulation [3] - Payment mechanism reforms are crucial for the commercialization of AI healthcare products, with policies supporting AI-assisted diagnosis and innovative payment models [4] Group 3 - Application scenarios are being expanded, with the government identifying key areas for AI in healthcare, creating a positive cycle of policy guidance and innovation [5] - The integration of AI with pharmaceutical manufacturing and healthcare services is encouraged, fostering a diversified innovation ecosystem [6] Group 4 - Shanghai is leading the way in medical AI development with the first provincial-level plan, aiming to create a nationally replicable model for AI in healthcare [7] - The plan emphasizes enhancing innovation sources, building support platforms, and creating comprehensive application scenarios in clinical and public health [8][9][10] Group 5 - Companies are focusing on three critical elements: application scenarios, data, and computing power, which are essential for breakthroughs in the AI healthcare industry [11][12] - There is a pressing need for high-value application scenarios, as many AI technologies face challenges in adapting to clinical and industry needs [13][14] - Data sharing and quality are significant concerns, with companies advocating for unified data-sharing mechanisms to overcome barriers [16][17] - The demand for computing power is high, and companies are calling for centralized computing resources to reduce costs and improve efficiency [17] Group 6 - The trend of companies expanding internationally is becoming essential, with different paths for AI in drug development and medical devices [18] - AI in drug development is characterized by a dual approach of licensing out and independent international expansion, focusing on regions with established clinical trial systems [19][20] - AI in medical devices is pursuing multiple strategies to adapt to global market needs, including remote surgery and tailored solutions [20] Group 7 - A comparison of capabilities between Chinese and American companies in various AI healthcare fields shows differences in market maturity and regulatory environments [30] Group 8 - Specialized medical models are gaining traction, with hospitals leading the deployment of AI models tailored to specific diseases [34] - Evidence-based medicine is being utilized to address challenges in AI reliability and accuracy [37][38] Group 9 - The emergence of embodied intelligence is expected to bridge the gap between digital healthcare and physical health services, focusing on autonomous medical interventions and human-robot collaboration [45][49][51] Group 10 - AI technology is fundamentally reshaping the healthcare industry by enhancing operational efficiency and expanding access to quality medical resources [54] - The shift from hospital-centered systems to personal health information systems marks a significant transformation in healthcare delivery, emphasizing proactive health management [56][60]

Core Viewpoint - The launch of the public hospital reform and high-quality development demonstration project in Xicheng District, Beijing aims to enhance healthcare services through the integration of artificial intelligence and digital technologies in medical practices [1][2] Group 1: Project Overview - The demonstration project will be implemented over three years, focusing on collaborative governance in healthcare, hierarchical diagnosis and treatment, comprehensive reform of public hospitals, and the empowerment of digital technology [1] - The project aims to create replicable and promotable "Xicheng experience" to improve regional healthcare service levels [1] Group 2: Key Tasks and Measures - The implementation plan includes four major tasks and 13 reform measures, emphasizing the sharing of medical resources and the establishment of four centers: medical imaging, testing, pathology, and telemedicine [1] - A "one bed for the entire district" sharing mechanism will be explored, along with pilot programs for unified procurement of drugs, consumables, and equipment to achieve cost reduction and efficiency [1] Group 3: Hospital Development - The project will clarify the functional positioning of district hospitals through "one hospital, one policy" and promote key renovation projects like the revitalization of hospitals and standardized construction of community health service centers [1] - There will be a focus on strengthening specialties in traditional Chinese medicine, rehabilitation, and addressing shortages in geriatrics, pediatrics, psychiatry, and infectious diseases [1] Group 4: Digital Integration - The initiative will deepen the integration of digital technologies, establishing a unified platform for district hospitals, community health, public health, and health information to eliminate information barriers [2] - The project will provide smart health monitoring devices for the elderly and key chronic disease populations, facilitating proactive and continuous health management [2]

Core Viewpoint - The integration of artificial intelligence (AI) with the improvement of people's livelihoods is emphasized, aiming to enhance daily work, learning, and living through AI applications, particularly in healthcare, education, and elderly care [1][2]. Group 1: AI and Social Needs - The development of AI should respond to real social needs, transitioning from laboratory innovations to practical applications in areas like education, healthcare, and elderly care [2]. - AI can enhance social governance and public service efficiency by utilizing comprehensive data, intelligent algorithms, and powerful computing capabilities, shifting service models from passive to proactive [2]. - A people-centered approach is essential to ensure AI development aligns with human welfare, preventing issues like algorithm bias and privacy violations [2]. Group 2: Current Challenges - Despite advancements, AI faces challenges in technical adaptability, group suitability, and institutional compatibility, with issues such as digital divides and inadequate ethical safeguards [3]. - There is a need to focus on key areas and demographics to balance the technological enthusiasm of AI with its service temperature, ensuring stable and beneficial applications in improving livelihoods [3]. Group 3: Targeted Solutions - In education, AI can facilitate personalized learning and resource sharing to promote equity and innovation [3]. - In healthcare, AI can assist in diagnostics and enhance health management throughout the patient lifecycle [3]. - In elderly care, AI can improve service systems through technology adaptation and resource integration [3]. Group 4: Inclusivity and Long-term Development - AI should aim for inclusivity by addressing the digital divide and providing tailored solutions for various demographics, such as the elderly and disabled [4]. - Long-term development requires a robust institutional framework, including top-level design, incentive mechanisms, and collaborative governance to ensure AI benefits reach all citizens [4].

Core Viewpoint - The report from Guojin Securities indicates that certain sectors, such as ophthalmology and dentistry, are expected to see improved conditions by 2025, with a potential reversal in the healthcare services sector by 2026 as pricing wars and procurement risks diminish, suggesting an opportunity for valuation recovery across the sector [1] Group 1: Industry Development - The industry has entered a mature development phase characterized by intrinsic growth and structural optimization [2] - National policies, such as the "Opinions on Promoting High-Quality Development of Service Consumption," provide a solid foundation for long-term industry growth [2] - The rebalancing of supply and demand is a key theme, with weaker small medical institutions exiting the market, leading to increased industry concentration and opportunities for leading companies to gain market share [2] Group 2: Market Dynamics - The growth of leading companies in 2025 will primarily stem from improved operational efficiency and market share consolidation [2] - The report maintains a positive outlook on the growth potential and development logic of the chain medical industry, particularly for companies with strong asset attributes, excellent organic growth, and clear expansion strategies [2] Group 3: Sector Opportunities - There is a long-term penetration rate improvement logic in core sectors, with significant growth potential in ophthalmology and dentistry [3] - For instance, the cataract surgery rate in China was approximately 2,794 cases per million in 2022, significantly lower than the over 10,000 cases per million in Western countries, indicating substantial room for growth [3] - Companies like Aier Eye Hospital and Tongce Medical are leveraging strategic initiatives to enhance their market positions and operational efficiencies [3] Group 4: AI Integration - The integration of AI in healthcare is expected to enhance service quality while managing operational costs, particularly in imaging diagnostics and clinical decision-making [4] - AI applications are reducing reliance on repetitive tasks for doctors and improving diagnostic standardization [4] Group 5: Commercialization of AI - The commercialization of AI in healthcare is entering an accelerated phase, with policies in major cities like Beijing and Shanghai beginning to include AI-assisted diagnostics in insurance coverage [5] - Companies with strong technological barriers and clear commercialization paths are expected to achieve rapid growth and improved profitability as they navigate the transition from technology to market maturity [5]

报告导读： 国家医保局印发《病理类医疗服务价格项目立项指南（试行）》，有望规范人 工智能辅助诊断市场。 12 月 19 日，国家医保局印发《病理类医疗服务价格项目立项指南（试行）》，我们认为人工智能辅助诊断市场有望更加规范，给予所处医疗器械行业增持 评级。 为贯彻落实《深化医疗服务价格改革试点方案》，推进全国医疗服务价格项目规范编制工作，按照"成熟一批、发布一批"的工作思路， 2025 年 12 月 19 日，国家医保局编制印发了《病理类医疗服务价格项目立项指南（试行）》，将已有价格项目规范整合为 28 项、加收项 3 项、扩展项 2 项。下一步，国家 医保局将指导各省医保局参考《病理类医疗服务价格项目立项指南（试行）》，制定全省统一的价格基准，由具有价格管理权限的统筹地区对照全省价格基 准，上下浮动确定实际执行的价格水平。 《病理类医疗服务价格项目立项指南（试行）》中的第一项及第二项，病理诊断费及病理诊断费（远程）中，明确规定扩展项【人工智能辅助诊断】，价格构 成为所定价格涵盖病理样本接收、判读、诊断、人工智能辅助诊断、出具报告并上传等步骤所需的人力资源和基本物质资源消耗。 以上内容节选自国泰海通证券已发布 ...

Investment Rating - The report assigns an "Accumulate" rating to the medical device industry, indicating a positive outlook for investment opportunities [4]. Core Insights - The National Healthcare Security Administration (NHSA) issued the "Guidelines for the Project Establishment of Pathology Medical Service Pricing (Trial)," which is expected to standardize the artificial intelligence-assisted diagnosis market [2][4]. - The guidelines consolidate existing pricing projects into 28 items, with 3 additional charges and 2 expansion items, aiming to create a unified pricing standard across provinces [4]. - The inclusion of "AI-assisted diagnosis" as an expansion item in the pricing guidelines is anticipated to regulate the market and stimulate research and development in the industry [4]. Summary by Sections - **Policy Implementation**: The NHSA's guidelines are part of a broader initiative to reform medical service pricing, promoting a structured approach to pricing in pathology services [4]. - **Pricing Structure**: The guidelines specify that the pricing for pathology diagnosis includes costs associated with sample reception, interpretation, diagnosis, AI assistance, and report generation [4]. - **Digital Transformation**: The requirement for medical institutions to upload pathology reports and digital images is expected to drive the adoption of digital technologies and facilitate nationwide sharing of diagnostic results [4].

（来源：新安晚报） 转自：新安晚报 国家医保局12月19日发布《病理类医疗服务价格项目立项指南（试行）》，明确将"人工智能辅助诊 断"列为病理诊断的扩展项，将人工智能辅助诊断纳入病理诊断价格项目的价格构成。 为推动人工智能在病理领域的应用，立项指南指导各地在定价时关注人工智能辅助诊断的相关资源投入 成本，在价格水平上进行整体调节和引导，为人工智能辅助诊断技术应用理顺收费路径。医疗机构可自 行决定是否选用人工智能辅助诊断技术、自行决定选用哪家企业的产品，具体收益分配由医疗机构与企 业自行协商确定。 临床检查中，影像、检验、病理是患者最常接触的三类检查方式。其中，病理被认为是医学诊断的"金 标准"，依托细胞病理、组织病理及分子病理等技术平台，通过对病变组织与细胞的精准分析，明确疾 病类型、肿瘤分型及关键基因突变，为临床诊疗方案的制定提供关键依据。 下一步，国家医保局将指导各省医保局参考此次立项指南，制定全省统一的价格基准，由具有价格管理 权限的统筹地区对照全省价格基准，上下浮动确定实际执行的价格水平。据新华社电 聚焦活检取样、样本处理、切片复制、病理染色、病理诊断等环节，立项指南将已有价格项目规范整合 为28项、 ...

新华社北京12月19日电（记者彭韵佳）国家医保局12月19日发布《病理类医疗服务价格项目立项指南 （试行）》，明确将"人工智能辅助诊断"列为病理诊断的扩展项，将人工智能辅助诊断纳入病理诊断价 格项目的价格构成。 ...